The medical records of 49 dogs with spontaneously occurring malignant tumors treated with doxorubicin-based chemotherapy protocols were evaluated for hematological toxicity. Protocols included vincristine, doxorubicin, and cyclophosphamide (VAC); 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC); doxorubicin and cyclophosphamide (AC); and doxorubicin and dacarbazine (ADIC). Prevalence of Grades 1, 2, or 3 toxicities were less than 30%, and the prevalence of Grade 4 toxicity alone was less than 5%. The frequency of sepsis was less than 2.5% in dogs treated with VAC, FAC, or AC, and it was 15% in dogs treated with ADIC. There were no significant differences in the prevalence or severity of hematological toxicity caused by VAC or AC. Five-fluorouracil, doxorubicin, and cyclophosphamide caused significantly more severe neutropenia than VAC or AC. The low prevalence of hematological complications makes these protocols acceptable for use in practice.
Skip Nav Destination
Article navigation
September/October 2000
Articles|
September 01 2000
Hematological toxicity of doxorubicin-containing protocols in dogs with spontaneously occurring malignant tumors
J Am Anim Hosp Assoc (2000) 36 (5): 422–426.
Citation
EA Ahaus, CG Couto, KD Valerius; Hematological toxicity of doxorubicin-containing protocols in dogs with spontaneously occurring malignant tumors. J Am Anim Hosp Assoc 1 September 2000; 36 (5): 422–426. doi: https://doi.org/10.5326/15473317-36-5-422
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionCiting articles via
Long-Term Survival of Primary Intracranial Histiocytic Sarcoma Through Surgical Resection and Low-Dose CCNU
Kyosuke Hidari, DVM, Yuya Nakamoto, DVM, PhD, James K. Chambers, DVM, PhD, Kazuyuki Uchida, DVM, PhD, Isao Mori, DVM, Miwa Nakamoto, DVM
Microfilaria in the Urine of a Dog with Concurrent Urinary Bladder Sarcoma
Nicole Schlette, DVM, Erin Burton, DVM, MS, DACVP, Amber Harris, DVM, DACVIM (Internal Medicine), Kendall Langsten, DVM, DACVP, Erik Olson, DVM, PhD, DACVP, Daniel Heinrich, DVM, DACVP
Chronic Myelomonocytic Leukemia with Central Nervous System Involvement in a Dog
Ilaria Tartari, DVM, Fabio Tocco, DVM, Giorgio Cancedda, DVM, Veronica Angioni, DVM, Marco Podda, DVM, Antonella Gallucci, DVM, PhD, DECVN, EBVS
Treatment Outcomes of Canine Orbital Meningiomas in Seven Cases
Akihiro Uno, DVM, Ryota Iwasaki, DVM, PhD, Takashi Mori, DVM, PhD
Transient Hypoadrenocorticism in a 7-Week-Old Kitten
Alba Planas Vintro, BVM, Linda G. Martin, DVM, MS, DACVECC, Cassidy L. Cordon, DVM, Sabrina N. Hoehne, Dr. med. vet., DACVECC, DECVECC, Elizabeth B. Davidow, DVM, DACVECC